keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan

keyword
https://www.readbyqxmd.com/read/28230062/triple-combination-therapy-in-the-treatment-of-hypertension-a-review-of-the-evidence
#1
REVIEW
R Düsing, B Waeber, M Destro, C Santos Maia, P Brunel
Hypertension is a serious public health concern with inadequate control of blood pressure (BP) worldwide. Contributing factors include low efficacy of drugs, underuse of combination therapies, irrational combinations, physicians' therapeutic inertia and poor adherence to treatment. Current guidelines recommend the use of initial (dual) combination therapy in high-risk patients for immediate BP response, better short- and long-term BP control, and continued/improved patient adherence. This article aims to review the existing evidence of triple-combination therapies with respect to efficacy, safety and adherence to treatment...
February 23, 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/28185709/heart-failure-guidelines-what-s-new
#2
REVIEW
Lampros Papadimitriou, Carine E Hamo, Javed Butler
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction...
January 11, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28178694/resolution-of-cheyne-stokes-respiration-after-treatment-of-heart-failure-with-sacubitril-valsartan-a-first-case-report
#3
Henrik Fox, Thomas Bitter, Dieter Horstkotte, Olaf Oldenburg
Sleep-disordered breathing (SDB) is highly prevalent in patients with heart failure (HF), and is known to be associated with a worse prognosis. The severity of central sleep apnea is thought to mirror cardiac dysfunction. The novel angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril has been shown to improve HF, but a relationship between treatment with ARNi and the severity of SDB has not yet been investigated. We report the case of a 71-year-old male with HF and SDB. Treatment with sacubitril/valsartan was associated with improved cardiac function, as shown by a reduction in the level of N-terminal prohormone of brain natriuretic peptide from 3,249 to 1,720 pg/mL, and an improvement in left-ventricular ejection fraction from 30 to 35%...
February 9, 2017: Cardiology
https://www.readbyqxmd.com/read/28178619/effect-of-qishenyiqi-pill-on-myocardial-collagen-metabolism-in-experimental-autoimmune-myocarditis-rats
#4
Shi-Chao Lv, Meifang Wu, Meng Li, Qiang Wang, Xiao-Jing Wang, Ao Zhang, Ling Xu, Jun-Ping Zhang
OBJECTIVE: To observe the effect of QiShenYiQi pill (QSYQ) on myocardial collagen metabolism in experimental autoimmune myocarditis rats, and to explore its mechanism of action. METHODS: Lewis rats underwent the injection of myocardial myosin mixed with freund's complete adjuvant were randomized into three groups: model, valsartan and QSYQ groups. And we treated rats which were injected phosphate buffered saline (PBS) mixed with freund's complete adjuvant as control group...
February 5, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28178430/nitric-oxide-synthesis-promoting-effects-of-valsartan-in-human-umbilical-vein-endothelial-cells-via-the-akt-adenosine-monophosphate-activated-protein-kinase-endothelial-nitric-oxide-synthase-pathway
#5
Yingshuai Zhao, Liuyi Wang, Shanshan He, Xiaoyan Wang, Weili Shi
Valsartan (VAL), an antagonist of angiotensin II receptor type 1, has antihypertensive and multiple cardiovascular protective effects. The pleiotropic functions of VAL are related to the increased synthesis and biological activity of intravascular nitric oxide (NO). In this study, the role and mechanisms of VAL in the synthesis of NO were examined in human umbilical vein endothelial cells (HUVECs). Ten µmol/L of VAL was used to treat EA.hy926 cells for 30 minutes, 1, 3, 6, 12, and 24 hours, and three concentrations of VAL (i...
February 8, 2017: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/28176581/correction
#6
(no author information available yet)
There was an error in our CPD article Chronic heart failure part 2: treatment and management (11 January). On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction ≤35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016)...
February 8, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28164602/effects-of-angiotensin-inhibitor-valsartan-on-the-expression-of-the-angiotensin-ii-1-receptor-matrix-metalloproteinases-2-and-9-in-human-bladder-cancer-cell-lines
#7
Delin Yang, Qian Huo, Ting Luan, Jiansong Wang, Zhaoran Tang, Haifeng Wang
BACKGROUND: In order to investigate how valsartan-the angiotensin II 1 receptor (AT1R) antagonist-affects the expressions of AT1R antigen, matrix metalloproteinases (MMPs) -2 and -9 in carcinoma of urinary bladder (CUB) cell lines with different invasive abilities. METHODS: Three cell lines, EJ-M3, EJ, and BIU-87, with different invasive abilities were cultured and treated with valsartan. Cell proliferation states were determined by the methyl thiazolyl tetrazolium (MTT) method...
August 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28158398/systolic-blood-pressure-cardiovascular-outcomes-and-efficacy-and-safety-of-sacubitril-valsartan-lcz696-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-results-from-paradigm-hf
#8
Michael Böhm, Robin Young, Pardeep S Jhund, Scott D Solomon, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Karl Swedberg, Michael R Zile, Milton Packer, John J V McMurray
No abstract text is available yet for this article.
February 1, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28158388/sacubril-valsartan-and-low-blood-pressure-in-heart-failure-with-reduced-ejection-fraction
#9
Rosa Maria Bruno, Stefano Taddei
No abstract text is available yet for this article.
January 30, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28133468/changing-the-treatment-of-heart-failure-with-reduced-ejection-fraction-clinical-use-of-sacubitril-valsartan-combination
#10
REVIEW
Edgardo Kaplinsky
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Neprilysin is an endopeptidase that breaks down several vasoactive peptides including natriuretic peptides (NPs), bradykinin, endothelin and angiotensin II (Ang-II)...
November 2016: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/28130773/identification-of-substandard-medicines-via-disproportionality-analysis-of-individual-case-safety-reports
#11
Zahra Anita Trippe, Bruno Brendani, Christoph Meier, David Lewis
INTRODUCTION: The distribution and use of substandard medicines (SSMs) is a public health concern worldwide. The detection of SSMs is currently limited to expensive large-scale assay techniques such as high-performance liquid chromatography (HPLC). Since 2013, the Pharmacovigilance Department at Novartis Pharma AG has been analyzing drug-associated adverse events related to 'product quality issues' with the aim of detecting defective medicines using spontaneous reporting. The method of identifying SSMs with spontaneous reporting was pioneered by the Monitoring Medicines project in 2011...
January 28, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28118578/novel-pure-component-contribution-algorithm-pcca-and-uhplc-methods-for-separation-and-quantification-of-amlodipine-valsartan-and-hydrochlorothiazide-in-ternary-mixture
#12
Shereen Mowaka, Maha A Hegazy, Hayam M Lotfy, Ekram H Mohamed
Two accurate and sensitive methods were developed and validated for the simultaneous determination of amlodipine (AML),valsartan (VAL), and hydrochlorothiazide (HCT) in their ternary mixture. The first method is a novel simple algorithm capable of extracting the contribution of each component from a mixture signal in which the components are partially or completely overlapped. It is based on the use of a coded function that eliminates the signal of interfering components using mean centering as a processing tool...
December 21, 2016: Journal of AOAC International
https://www.readbyqxmd.com/read/28104434/effects-of-human-opiorphin-on-food-intake-and-water-intake-in-mice-following-central-administration
#13
Yong Chen, Xiao-Zhu Tian, Lu Bai, Ze-Qi Liu, Xing-Peng Xiao, Pu Liu, Xiang-Kai Li
Human opiorphin plays an important pharmacological functions in rats or mice. The present study was performed to investigate effects and underlying mechanism of central injected opiorphin on food intake and water intake in mice. Intracerebroventricularly (i.c.v.) administered opiorphin (5-20μg/kg) dose-dependently suppressed food intake in fasted mice, but had no influence on food intake in freely feeding mice. The cumulative food intake was significantly decreased at 60min after injection of 10 and 20μg/kg opiorphin and the food intake was significantly reduced during the 20-60min period after treatment...
January 16, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28104105/effects-of-amlodipine-and-valsartan-on-blood-pressure-variability-and-pulse-wave-velocity-in-hypertensive-patients
#14
Rufeng Shi, Kai Liu, Di Shi, Qi Liu, Xiaoping Chen
OBJECTIVES: Antihypertensive therapy is effective to control blood pressure (BP) and to prevent cardiovascular events, but the further treatment strategies for patients who cannot achieve goal BP with low-dose monotherapy is still under dispute. Our study investigates the effects of high-dose amlodipine and valsartan and their low-dose combination on blood pressure variability (BPV) and pulse wave velocity (PWV) to provide references for clinical medication. MATERIALS AND METHODS: This study was a prospective, randomized, parallel, case-controlled trial performed in a medical center...
January 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28101460/captopril-and-valsartan-may-improve-cognitive-function-through-potentiation-of-the-brain-antioxidant-defense-system-and-attenuation-of-oxidative-nitrosative-damage-in-stz-induced-dementia-in-rat
#15
Yasaman Arjmand Abbassi, Mohammad Taghi Mohammadi, Mahsa Sarami Foroshani, Javad Raouf Sarshoori
Purpose: Previous findings have shown the crucial roles of brain renin-angiotensin system (RAS) in pathogenesis of Alzheimer's disease (AD). Since RAS inhibitors may have beneficial effects on dementia and cognitive function in elderly people, the aim of present study was to examine the neuroprotective actions of captopril and valsartan on memory function and neuronal damage in experimental model of AD. Methods: Adult forty male Wistar rats (220-280g) were randomly divided into 5 groups; Control, Vehicle, Alzheimer and treatment groups...
December 2016: Advanced Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28099346/liuwei-dihuang-pill-treats-diabetic-nephropathy-in-rats-by-inhibiting-of-tgf-%C3%AE-smads-mapk-and-nf-kb-and-upregulating-expression-of-cytoglobin-in-renal-tissues
#16
Zhong Ju Xu, Shi Shu, Zhi Jie Li, Yu Min Liu, Rui Yi Zhang, Yue Zhang
Liuwei Dihuang pill (LDP) was assessed for its effects on renal deficiency.90 STZ induced DN rats were divided into groups (n = 22) without treatment (STZ) and LDP treated (STZ-L) (n = 23), Zhenwu decoction treated (STZ-Z) (n = 22), and valsartan treated (STZ-V) (n = 23) groups, with 16 normal control rats. Total urine protein (TP), blood urea nitrogen (BUN), and serum creatinine (Cr) were measured. Superoxide dismutase (SOD), nitric oxide synthase (NOS), and malondialdehyde (MDA) concentrations as well as expression/phosphorylation of SMAD3, SMAD2, and α-SMA, TGF-β, RI /II, P38, ERK, and NF-kB in renal tissues were determined...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28093841/effect-of-valsartan-on-kidney-outcomes-in-people-with-impaired-glucose-tolerance
#17
Gemma Currie, M Angelyn Bethel, Björn Holzhauer, Steven M Haffner, Rury R Holman, John J V McMurray
AIMS: Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and the subsequent development of end-stage renal disease (ESRD) in patients with type 2 diabetes. We aimed to examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance (IGT). METHODS: In a double-blind randomized trial, 9306 patients with IGT were assigned to valsartan (160 mg daily) or placebo. The co-primary endpoints were the development of diabetes and two composite cardiovascular outcomes...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28093466/effects-of-sacubitril-valsartan-versus-olmesartan-on-central-hemodynamics-in-the-elderly-with-systolic-hypertension-the-parameter-study
#18
Bryan Williams, John R Cockcroft, Kazuomi Kario, Dion H Zappe, Patrick C Brunel, Qian Wang, Weinong Guo
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure >60 mm Hg, indicative of arterial stiffness. Patients (n=454; mean age, 67...
March 2017: Hypertension
https://www.readbyqxmd.com/read/28090038/combination-therapy-with-ombitasvir-paritaprevir-ritonavir-for-dialysis-patients-infected-with-hepatitis-c-virus-a-prospective-multi-institutional-study
#19
Ken Sato, Kenichi Hosonuma, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Hiroshi Ohnishi, Hiroaki Okamoto, Masanobu Yamada
Hepatitis C virus (HCV) infection is common in dialysis patients worldwide and nosocomial HCV spread within dialysis facilities continues to develop. Combination therapy with daclatasvir and asunaprevir (DCV/ASV) that has proven efficacy for dialysis patients infected with genotype 1b HCV (HCV/1b) has several concerns in Japan. The recently available combination therapy with ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r) is not contraindicated in patients with chronic renal failure and has more safety profile and shorter treatment period than that with DCV/ASV...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28089685/evaluation-of-drug-drug-interaction-potential-between-sacubitril-valsartan-lcz696-and-statins-using-a-physiologically-based-pharmacokinetic-model
#20
Wen Lin, Tao Ji, Heidi Einolf, Surya Ayalasomayajula, Tsu-Han Lin, Imad Hanna, Tycho Heimbach, Christopher Breen, Venkateswar Jarugula, Handan He
Sacubitril/valsartan (LCZ696) has been approved for the treatment of heart failure. Sacubitril is an in vitro inhibitor of OATPs. In clinical studies, LCZ696 increased atorvastatin Cmax by 1.7-fold and AUC by 1.3-fold, but had little or no effect on simvastatin or simvastatin acid exposure. A PBPK modelling approach was applied to explore the underlying mechanisms behind the statin-specific LCZ696 drug interaction observations. The model incorporated OATP-mediated clearance (CLint,T) for simvastatin and simvastatin acid to successfully describe the PK profiles of either analyte in the absence or presence of LCZ696...
January 12, 2017: Journal of Pharmaceutical Sciences
keyword
keyword
16092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"